Omapatrilat Versus Lisinopril: Efficacy and Neurohormonal Profile in Salt-Sensitive Hypertensive Patients
Omapatrilat Versus Lisinopril: Efficacy and Neurohormonal Profile in Salt-Sensitive Hypertensive Patients
复制标题
奥马帕曲拉与赖诺普利：盐敏感性高血压患者的疗效和神经激素特征
作者：
V. Campese;K. Lasseter;C. Ferrario;W. Smith;M. Ruddy;C. Grim;Ronald D. Smith;R. Vargas;M. F. Habashy;O. Vesterqvist;C. Delaney;W. Liao
奥马曲拉是一种血管肽酶抑制剂，同时抑制中性内肽酶和ACE。比较了奥马曲拉和赖诺普利治疗盐敏感性高血压患者的疗效和激素水平。在入组时，停用降压药物，患者接受单盲安慰剂。在第15天，进行盐敏感性测定。盐敏感性高血压患者在5 - 10天内返回进行动态舒张压、动态收缩压和心钠素的基线评估。盐敏感性高血压患者随机接受双盲omapatrilat（n=28）或赖诺普利（n=33），初始剂量为10 mg，持续1周，然后分别增加至40和20 mg，持续3周。在研究结束时评估动态血压和尿心钠素。Omapatrilat和赖诺普利均显著降低24小时动态舒张压和收缩压;然而，与赖诺普利相比，Omapatrilat显著降低24小时动态舒张压（P =0.008）、动态收缩压（P =0.004）和动态平均动脉压（P =0.005）。两种药物在24小时内均有效抑制ACE。奥马曲拉显著增加0- 24小时（3.8倍）和12- 24小时（2倍）尿心钠素排泄量（P <0.001）;赖诺普利无变化。与赖诺普利相比，奥马曲拉显著增加0 ~ 24小时和4 ~ 8小时尿cGMP排泄量（P <0.001）。两种药物均无利尿、利钠或利钾尿作用。总之，在盐敏感性高血压患者中，omapatrilat表现出血管肽酶抑制剂的激素特征，并且比赖诺普利更能降低动态舒张压和收缩压。
Omapatrilat, a vasopeptidase inhibitor, simultaneously inhibits neutral endopeptidase and ACE. The efficacy and hormonal profile of omapatrilat and lisinopril were compared in salt-sensitive hypertensive patients. On enrollment, antihypertensive medications were withdrawn, and patients received a single-blind placebo. On day 15, salt-sensitivity determinations were made. Salt-sensitive hypertensive patients returned within 5 to 10 days for baseline evaluations of ambulatory diastolic blood pressure, ambulatory systolic blood pressure, and atrial natriuretic peptide. Salt-sensitive hypertensive patients were randomized to receive double-blind omapatrilat (n=28) or lisinopril (n=33) at initial doses of 10 mg for 1 week, increasing to 40 and 20 mg, respectively, for an additional 3 weeks. Ambulatory blood pressure and urinary atrial natriuretic peptide were assessed at study termination. Both omapatrilat and lisinopril significantly reduced mean 24-hour ambulatory diastolic and systolic blood pressures; however, omapatrilat produced significantly greater reductions in mean 24-hour ambulatory diastolic blood pressure (P =0.008), ambulatory systolic blood pressure (P =0.004), and ambulatory mean arterial pressure (P =0.005) compared with values from lisinopril. Both drugs potently inhibited ACE over 24 hours. Omapatrilat significantly (P <0.001) increased urinary excretion of atrial natriuretic peptide over 0- to 24-hour (3.8-fold) and 12- to 24-hour (2-fold) intervals; lisinopril produced no change. Omapatrilat significantly (P <0.001) increased urinary excretion of cGMP over the 0- to 24- and 4- to 8-hour intervals compared with that from lisinopril. Neither drug had a diuretic, natriuretic, or kaliuretic effect. In conclusion, in salt-sensitive hypertensive patients, omapatrilat demonstrated the hormonal profile of a vasopeptidase inhibitor and lowered ambulatory diastolic and systolic blood pressures more than lisinopril.
影响因子：
3
作者：
H. H. Chen-H.;J. Burnett
通讯作者：
H. H. Chen-H.;J. Burnett
影响因子：
8.3
作者：
Campese, VM;Tawadrous, M;Raij, L
通讯作者：
Raij, L
DOI：
--
发表时间：
1999
期刊：
Journal of hypertension. Supplement : official journal of the International Society of Hypertension
影响因子：
--
作者：
BurnettJr,JC
通讯作者：
BurnettJr,JC